AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
January 25, 2017
12:00 PM- 5:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Dan Lindell
Kathleen Bryant
Stephen Chakmakian
Robert Marotz – arrived after the minutes vote
Suzanne Campbell
Lydia Nesemann
Gloria Abril
Cindy Komar
Shawn McMahon
James Hargrave

AHCCCS Staff:
Sara Salek
Robin Davis
Suzi Berman
Kathy Bashor

Magellan Medicaid Admin:
Sarah Martinez

Members Absent:
Otto Uhrik
Johanna Kowalik
Berkley Olvera
Mohamad Ramadan
Olivia Young
1. Dr. Sara Salek called the meeting to order at 12:09 PM and welcomed committee members, staff, and guest presenters.
   a. P&T Minutes from October 19, 2017 were reviewed.
      i. A Motion was made by Lydia Nesemann.
      ii. The Motion was seconded by Suzanne Campbell.
      iii. 10 committee members voted in favor of approving the minutes.
      iv. No committee members opposed or abstained.

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEWS

1. Glucocorticoids, Inhaled
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony: None
   c. Public Testimony: None

2. Executive Session – Closed to the Public

3. Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes.
   a. Committee members voted unanimously to keep the following agents on the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
      i. Glucocorticoids, Inhaled
         1. Symbicort
         2. Advair Diskus
         3. Dulera
         4. Asmanex
         5. Qvar
         6. Flovent HFA
         7. Pulmicort Respules
7-DAY OPIOID LIMIT: SARA SALEK, AHCCCS

1. In October, an executive order was signed by Governor Ducey requiring Medicaid and State Employee insurance programs to limit short acting Opioids in Opioid naïve individuals. The order specifies the initial fill for the adult population is limited to a seven day supply. In the pediatric population, the initial fill and all subsequent refills are limited to a 7 day supply.

2. AHCCCS issued a policy, which was available for public comment from December 14, 2016-December 28, 2016. AHCCCS is currently revising and finalizing the policy which will be distributed to the health plans by 2/1/17 for an April 1, 2017 implementation.

FOLLOW UP: ONCOLOGY SUBCOMMITTEE: SUZI BERMAN

1. A recommendation was made that all of the older Oncology agents currently listed on the AHCCCS Drug List be available without a prior authorization requirement. A notation will be made on the Drug List that all other agents will be available through the prior authorization process.
   a. 11 committee members voted in favor of the recommendations.
   b. No committee members voted against the recommendations.
   c. No committee member abstained.

FOLLOW UP: HIV SUBCOMMITTEE: SUZI BERMAN

1. A recommendation made that all antiretroviral agents currently listed on the AHCCCS Drug List in the HIV class will be made available without prior authorization with exception of those with alternative use or special circumstances. The agents that are currently on the Drug List with prior authorization required include Truvada, Selzentry, and Fuzeon. Any future new agents in the HIV class will be brought to the P&T for a new drug review with recommendations on whether a PA will be required.
   d. 11 committee members voted in favor of the recommendation.
   e. No committee members voted against the recommendation.
   f. No committee member abstained.

2. AHCCCS will review federal guidance regarding prophylactic use of HIV agents for use with HIV non-infected individuals and present information at a future P&T Meeting.

BIOSIMILAR UPDATE - INFLECTRA 9infliximab-dyyb): SUZI BERMAN

a. Inflectra
   a. Recommendation is to continue to cover Brand Only Remicade because it is the more cost effective product to the state. Inflectra is a physician administered drug.
      i. 11 committee members voted in favor of the recommendations.
      ii. No committee members voted against the recommendations.
      iii. No committee member abstained.
NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: SUZI BERMAN

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
   a. Bromsite- Bromfenac Ophthalmic 0.075%
      i. Recommendation is to not add Bromsite to the AHCCCS Drug List because there are other Bromfenac Ophthalmic products available with similar efficacy and they are more cost effective.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.
   
   b. Byvalson – Nebivolol HCL / Valsartan
      i. Recommendation is to not add Byvalson to the AHCCCS Drug List because it is more cost effective to prescribe the drugs individually.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.
   
   c. Cuvitru – Immune Globulin SQ
      i. Recommendation is to not add to the AHCCCS Drug List. It is available through the prior authorization process.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.
   
   d. Otovel - Ciprofloxacin 0.3% / Fluocinolone Otic 0.025%
      i. Recommendation is to not add Otovel because the products are available separately and there are other combination products available which are more cost effective.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.
   
   e. Relistor – Methylnaltrexone Bromide
      i. Recommendation is to not add this drug to the AHCCCS Drug List because there are many products available that are more cost effective. Relistor is available through the prior authorization process based on medical necessity.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
3. No committee member abstained

f. Sustol - Granisetron ER (inj)
   i. Recommendation is to not add this drug to the AHCCCS Drug List because it is limited as a
      physician administered drug.
      1. No vote: This drug may be billed using a medical claim based on medical necessity.

   g. Yosprala – Aspirin / Omeprazole
      i. Recommendation is to not add Yosprala to the AHCCCS Drug List because enteric coated aspirin
         and omeprazole are currently available as individual products.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.

   h. Zurampic – Lesinurad
      i. Recommendation is to not add Zurampic to the AHCCCS Drug List because it is a 2nd line
         therapy. Zurampic is available through prior authorization based on medical necessity.
         1. 11 committee members voted in favor of the recommendations.
         2. No committee members voted against the recommendations.
         3. No committee member abstained.

**DRUG PRICING: LYDIA NESEMANN**

1. Information was provided to the committee regarding on current pricing of multiple agents in several
   classes. Recommendations were made to the committee to remove costly agents where a less costly
   alternative is available, add prior authorization and quantity limits to certain agents, and add cost
   efficient alternatives which have become available.
   The recommendations are provided in a separate document located on the AHCCCS website at
   [www.azahcccs.gov](http://www.azahcccs.gov) under Pharmacy, and then click o the following headers; Pharmacy & Therapeutics
   Committee; then Agendas & Meeting Minutes; 2017; January 25, 2017 meeting documents; and finally
   AHCCCS P&T Recommendations for Generic Drugs and Valeant Pharmaceutical Products.

2. A vote was taken to accept the changes requested.
   a. 11 committee members voted in favor of the recommendations.
   b. No committee members voted against the recommendations.
   c. No committee member abstained.
NEXT MEETING DATES

2017 Meeting Dates:
Thursday, April 13, 2017
Monday, July 10, 2017,
Thursday October 12, 2017

ADJOURNMENT

The meeting adjourned at 3:04 PM.
Minutes recorded by Robin Davis

Suzanne Berman, RPh  April 13, 2017
Suzanne Berman, RPh  Date
Director of Pharmacy Services